Abstract (EN):
Herpes Simplex Virus type 1 (HSV-1) vectors are known to inhibit nociceptive transmission at the spinal cord after peripheral
applications. Similar approaches may also be useful when applied at the supraspinal pain control system as the system includes
pronociceptive (facilitatory) components. We performed a study aimed to analyse the migration of HSV-1 along with the inhibition of
pronociception from the medullary dorsal reticular nucleus (DRt), a major facilitatory component of the supraspinal pain control
system. To study the migration, a HSV-1 vector expressing lacZ under control of the human cytomegalovirus (hCMV) promoter was
injected in the DRt and the expression of b-galactosidase (b-gal) was detected at 2, 4, 7, 10 and 14 days. Numerous b-galimmunoreactive
neurons were observed at the injection site until day 4, and at some of the brain areas projecting to the DRt until day
7. To block the pronociceptive effects of the DRt, a HSV-1 vector expressing the preproenkephalin transgene, under the control of
hCMV promoter, was injected into the DRt. Behavioural evaluation was performed at the time-points referred above, using the paw
withdrawal latency test to evaluate thermal nociceptive responses. Anti-hyperalgesic effects persisted during 4 days, decreasing
after that time-point. The present study demonstrates that selective migration of HSV-1 should be considered in gene therapy
strategies based on HSV-1 injections into the brain. The study also shows that it is possible to decrease pain facilitation from the brain
using opioidergic inhibition of pronociceptive supraspinal areas.
Language:
Portuguese
Type (Professor's evaluation):
Scientific
Contact:
Prof. I. Tavares, Institute of Histology and Embryology